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Background. The epidemiology of antibiotic-resistant Enterobacteriaceae intestinal carriage in healthy US children has not
been well characterized.
Methods. Children between 14 days and 14 years of age were enrolled during well-child visits in Oakland, California, Kansas
City, Kansas, and Nashville, Tennessee, between December 2013 and March 2015. Data on recent antibiotic use by the child and
travel and hospitalization history of all members of each child’s household were obtained with a risk-factor survey. Stool specimens
collected from the subjects were screened for extended-spectrum β-lactamase-producing (ESBL-P) bacteria using CHROMagar
ESBL medium. Putative ESBL-P Escherichia coli and Klebsiella colonies underwent phenotypic confirmation by double-disk synergy
testing; confirmed third-generation cephalosporin-resistant (3GCR) isolates underwent additional antibiotic-susceptibility testing.
Results. In 519 subjects, the overall 3GCR Enterobacteriaceae carriage rate was 4.4% (n = 23) and ranged from 3.4% to 5.1%
among the study sites. The ESBL-P Enterobacteriaceae carriage rate was 3.5% (n = 18). The rates of 3GCR Enterobacteriaceae carriage was highest in 1 to <2 year olds at 6.5%, and was 5.2% in <5 year-olds vs 1.7% in ≥5-year-olds (P = .11). 3GCR and ESBL-P
Enterobacteriaceae carriage was associated with international travel within the previous year; 11.1% of ESBL-P Enterobacteriaceae
carriers reported this history compared with 1.6% of noncarriers (P = .004). No other queried factor was found to increase risk. Of
the 24 analyzed 3GCR isolates, 58% were multidrug resistant.
Conclusions. The 3GCR Enterobacteriaceae carriage rate exceeds 5% in healthy US children <5 years of age. International travel
within the previous year increased the risk of 3GCR and ESBL-P Enterobacteriaceae carriage. In contrast, we found no differences
in the rates of hospitalization or recent antibiotic exposure between carriers and noncarriers. Young children, who have the highest
prevalence of colonization, might be a sentinel population to study to gain a better understanding of community sources of antibiotic-resistant Enterobacteriaceae.
Keywords. ESBL-producing Enterobacteriaceae intestinal carriage; extended-spectrum β-lactamase (ESBL); multidrug-resistant Gram-negative bacteria; third-generation cephalosporin-resistant Enterobacteriaceae (3GCR).

Infections caused by extended-spectrum β-lactamase-producing (ESBL-P) Enterobacteriaceae and other antibiotic-resistant
(AR) Gram-negative bacteria are steadily rising in various
healthcare settings [1–3]. This trend includes children; US
laboratory surveillance data between 1999 and 2011 revealed
a 3- to 5-fold increase in the proportions of pediatric Gramnegative bacterial isolates that were ESBL-P or third-generation
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cephalosporin resistant (3GCR) (to 0.92% and 3%, respectively) [3]. Although inpatient carriage rates for ESBL-P
Enterobacteriaceae are the highest and exceed 10% in many
intensive care units, individual cases frequently originate in the
community and in patients without significant medical comorbidity [3–5]. 3GCR and ESBL-P Enterobacteriaceae infections
are often multidrug resistant, and management in children can
be particularly challenging because of the limited therapeutic
options [5].
Asymptomatic intestinal carriage of AR Enterobacteriaceae
can both follow and precede clinical infection [5–7]. Risk factors for acquisition and colonization of AR Enterobacteriaceae
in children are not well characterized; the studies that are available identified primarily carriers after an index infection and
found underlying neurologic and other medical conditions,
along with recent antibiotic intake, to be predisposing factors
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Intestinal Carriage of Third-Generation CephalosporinResistant and Extended-Spectrum β-Lactamase-Producing
Enterobacteriaceae in Healthy US Children

METHODS
Study Design and Participants

This investigation was conducted as a substudy of a larger multicenter study on the epidemiology of pediatric gastroenteritis
by the New Vaccine Surveillance Network (NVSN), funded by
the US Centers for Disease Control and Prevention. Subjects
of this AR Enterobacteriaceae colonization study were included
after being enrolled as healthy controls in the primary NVSN
study. Participating sites in this study were UCSF Benioff
Children’s Hospital Oakland in Oakland, California (OAK),
Children’s Mercy Hospital in Kansas City, Missouri, (KC), and
Monroe Carrel Jr. Children’s Hospital at Vanderbilt in Nashville,
Tennessee (NASH).
Children between 14 days and 14 years of age were enrolled
during well-child visits at their primary clinic. As healthy controls in the NVSN study, exclusion criteria were being immunocompromised, having had diarrhea or vomiting in the previous
14 days, and having had acute respiratory infection symptoms
in the previous 3 days. Participants of this substudy underwent
a brief survey that queried antibiotic intake by the child in
the previous 3 months and international travel and/or hospitalization in any HH member and foreign visitors to the HH
in the previous year (see the questionnaire in Supplementary
Appendix).
Specimen Processing, Laboratory Analyses, and Definitions

According to the protocol of the NVSN study, stool specimens
from the subject typically were obtained at the time of enrollment; when this was not possible, families were provided a

container in which to collect and submit stool within 5 days
by either direct drop-off at the study site or a study-arranged
courier. After stool receipt, a separate aliquot of approximately 1 g/0.5 ml of stool was prepared in a 1-ml solution of
sterile Luria broth with 20% glycerol specifically for this AR
Enterobacteriaceae colonization study.
For initial screening for the presence of AR Enterobacteriaceae,
1 µL of the stool solution described above was streaked directly
onto ESBL CHROMagar (CHROMagar, Paris, France) medium
plates. The ESBL CHROMagar medium and plates were prepared from a prep powder according to product instructions at
each of the 3 sites. Preparation of the stool solution and inoculation onto the ESBL CHROMagar medium plates typically were
performed on the day of stool receipt; in the infrequent situation when this process was not possible (eg, specimen received
on the weekend or another time when the laboratory coordinator was not available), the prepared stool aliquots were generally
maintained at 2 to 8°C and tested within 2 to 3 days.
Inoculated ESBL CHROMagar plates were incubated at
37°C for 18 to 24 hours and then assessed for colony growth.
Klebsiella pneumoniae (strain ATCC 700603) and Escherichia
coli (strain ATCC 25922) were used as positive and negative
controls, respectively. Non–ESBL-P bacteria are inhibited by
ESBL CHROMagar medium; colonies that grow are putative
ESBL producers, and different species have distinct colors [19].
Putative ESBL-P E coli and Klebsiella colonies were subcultured
to establish pure colonies, which were placed in Luria broth
with 20% glycerol and maintained at −80°C until further analysis. Matrix-assisted laser desorption/ionization–time-of-flight
mass spectrometry (Bruker Daltonics, Inc, Billerica, MA) was
performed on all putative (CHROMagar medium-recovered)
ESBL-P Enterobacteriaceae colonies for bacteriologic species
identification/confirmation.
All putative ESBL-P E coli and Klebsiella colonies underwent
standard double-disk synergy testing on Muller-Hinton agar
(BD Difco, Sparks, MD) following Clinical Laboratory Standards
Institute (CLSI) guidelines [20]. Briefly, bacterial colonies were
tested with the third-generation cephalosporins cefotaxime
(30 µg) and ceftazidime (30 µg) alone and in combination with
clavulanic acid (10 µg); the ESBL phenotype was defined as a
≥5-mm increase in the zone of inhibition with the combination
of a third-generation cephalosporin with clavulanic acid when
compared to the third-generation cephalosporin alone. Thirdgeneration cephalosporin resistance was defined as nonsusceptibility (intermediate susceptibility or resistance) to either
cefotaxime or ceftazidime (nonsusceptible zones of inhibition:
cefotaxime, <23 mm; ceftazidime, <18 mm).
All confirmed 3GCR and ESBL-P E coli and Klebsiella isolates underwent additional antibiotic testing on Muller-Hinton
agar with disks of amoxicillin-clavulanic acid, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, aztreonam, nalidixic
acid, meropenem, ampicillin, cephalothin, ceftriaxone and
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[5–9]. In adults, foreign travel—particularly to certain regions
and even after relatively short trips—has been associated with
significant rates of new fecal carriage of ESBL-P bacteria [10–
13]. Similarly, it has been increasingly recognized that the widespread, global dissemination of ESBLs at the general population
level (particularly of the CTX-M enzymes) has resulted in communities with a high prevalence of ESBL carriers [14].
Community-based studies of pediatric AR Enterobacteriaceae
carriage have revealed rates that vary widely, from <3% in young
Swedish children (ESBL-P) to 4% to 8% in the Netherlands
(3GCR) and >20% in sites in Spain and Africa (ESBL-P) [15–
18]. From North America, however, AR bacterial intestinal
carriage data at the community level are generally lacking, especially in children [14]. In this investigation, fecal specimens of
healthy children from 3 urban US centers were tested for the
presence of ESBL-P and 3GCR Enterobacteriaceae to determine rates of intestinal carriage. Basic healthcare exposures and
travel in household (HH) members were queried and analyzed
as risk factors for colonization. In addition, recovered 3GCR
Enterobacteriaceae isolates were tested for susceptibility to relevant antibiotic classes.

cefepime (BD BBL, Franklin Lakes, NJ) and ciprofloxacin, tetracycline, cefaclor, gentamicin, amikacin, and imipenem (Hardy
Diagnostics, Santa Maria, CA). Antimicrobial zones of inhibition were interpreted according to CLSI guideline breakpoints
[20]. Multidrug resistance was defined as nonsusceptibility to
≥1 agent in ≥3 antimicrobial classes.

Table 1. 3GCR, ESBL-P, and MDR Eb Carriage

Statistics

Ethics

The protocol was approved by the institutional review board/
ethics committee at each participating site and the Centers for
Disease Control and Prevention. Informed consent for performing the risk-factor survey and stool specimen laboratory
testing was obtained from the legal guardians of each participant (all ≤14 years of age).

Site (Total No. of Subjects Tested)

3GCR

ESBL-P

MDR

Oakland (176)

3.4 (6)

3.4 (6)

3.4 (6)

Kansas City (177)

5.1 (9)

3.4 (6)

1.7 (3)

Nashville (166)

4.8 (8)

3.6 (6)

2.4 (4)

Total (519)

4.4 (23)

3.5 (18)

2.5 (13)

Abbreviations: 3GCR, third-generation cephalosporin resistant; Eb, Enterobacteriaceae; ESBL-P, extended-spectrum β-lactamase producing (confirmed by double-disk diffusion testing); MDR, multidrug resistant
(defined as nonsusceptible to ≥1 agent in ≥3 antimicrobial classes).

confirmed ESBL-P, and the overall ESBL-P Enterobacteriaceae
carriage rate was 3.5%. The carriage rates for 3GCR and ESBL-P
Enterobacteriaceae in 1- to <2-year-old children were 6.5%
and 5.7%, respectively (Table 2). The carriage rates for 3GCR
Enterobacteriaceae were 5.2% for <5-year-olds and 1.7% for
≥5-year-olds (P = .11).
Completed risk-factor questionnaires from all 3GCR and
ESBL-P Enterobacteriaceae carriers and 489 (98.6%) of 496 noncarriers were available; the associations of 3GCR and ESBL-P
Enterobacteriaceae carriage with queried risk factors are presented in Table 3. 3GCR and ESBL-P Enterobacteriaceae carriage was associated with HH member foreign travel within the
preceding year; for ESBL-P Enterobacteriaceae, 11.1% of carriers
versus 1.6% of noncarriers (P = .004) had personal travel abroad.
At OAK, where travel rates were highest among the 3 sites, 50%
(3 of 6) of 3GCR and ESBL-P Enterobacteriaceae carriers had a
HH travel history versus 11.2% of the noncarriers (P = .005).
The countries that 3GCR and ESBL-P Enterobacteriaceae carriers and their HH members visited were Mexico, Nepal, the
Dominican Republic, and Vietnam. Rates of hospitalization in
the previous year and of having had any antibiotic exposure in
the previous 3 months did not differ between carriers and noncarriers (for both 3GCR and ESBL-P Enterobacteriaceae).
Two distinct 3GCR Enterobacteriaceae isolates were analyzed
from a single carrier; of the 24 analyzed isolates, 23 were 3GCR E

Table 2. 3GCR and ESBL-P Eb Carriage According to Age
Eb Carriage Rate (% [Total No. of Carriers])

RESULTS

Between December 2013 and March 2015, a total of 761 subjects from the 3 sites were enrolled, and 519 (68.2%) submitted
a stool specimen. The median age of the subjects with a stool
specimen was 18 months; 51.1% were female.
Twenty-three analyzed subjects harbored 3GCR
Enterobacteriaceae in their stool, for an overall intestinal carriage rate of 4.4%. Site-specific rates varied from 3.4% at OAK
to 5.1% at KC (Table 1). Of the 3GCR intestinal carriers, 60.9%
were female (P = .36). Of the 3GCR isolates, 78% (n = 18) were
236 • JPIDS 2018:7 (September) • Islam et al

Age Group (Total No. of Subjects)

3GCR

ESBL-P

0 to <1 y (178)

4.5 (8)

2.2 (4)

1 to <2 y (123)

6.5 (8)

5.7 (7)

2 to <3 y (60)

5.0 (3)

5.0 (3)

3 to <4 y (20)

5.0 (1)

5.0 (1)

4 to <5 y (23)

4.3 (1)

4.3 (1)

5 to <6 y (33)

0 (0)

0 (0)

6 to <7 y (19)

5.3 (1)

5.3 (1)

7 to 14 y (63)

1.6 (1)

1.6 (1)

Abbreviations: 3GCR, third-generation cephalosporin resistant; Eb, Enterobacteriaceae; ESBL-P, extended-spectrum β-lactamase producing (confirmed by double-disk diffusion testing).

Downloaded from https://academic.oup.com/jpids/article-abstract/7/3/234/3868858 by Children's Mercy Hospital user on 11 December 2018

Sample sizes for analysis and subject enrollment targets were
governed primarily by feasibility considerations and what was
anticipated to be achievable during a remaining year of the main
NVSN surveillance study. Also, an absence of baseline data on
AR Enterobacteriaceae carriage in healthy US children, along
with uncertainties in the distribution of hypothesized risk factors (eg, proportion of subjects with foreign travel in HH members), challenged power calculations. A target of approximately
500 healthy controls who had submitted stool specimens was
set and divided nearly evenly among the 3 participating sites.
Intestinal carriage was defined as having the presence of at
least 1 colony of the specific AR Enterobacteriaceae in the subject’s
stool specimen. Descriptive statistics for intestinal 3GCR and
ESBL-P Enterobacteriaceae carriage for various demographic
groups were generated. 3GCR and ESBL-P Enterobacteriaceae
carriers were compared with noncarriers for association with
potential risk factors by χ2 testing; statistical significance was
set at a P value of <.05. The small sample of identified AR
Enterobacteriaceae carriers, and subject subgroups (eg, according to age or reporting HH international travel), challenged the
reliability of multivariable methods; thus, these methods were
not performed. Statistical analysis was performed within the
RedCAP 6.13.3 database system (Vanderbilt University) and
with MedCalc 16.4.3 (MedCalc, Ostend, Belgium).

Eb Carriage Rate (% [Total No. of Carriers])

Table 3.

Risk Factors for 3GCR and ESBL-P Eb Carriage
3GCR Eb (%)

Risk Factor

ESBL-P Eb (%)

Noncarriers

Any antibiotic in previous 3 mo

8.7

8.6

Child hospitalizedb

4.3

4.3

21.7

12.9

Any HH member admitted to ICUb

4.3

Foreign travelb by childc
Foreign travelb by HH member and not child

Any HH member hospitalizedb

Foreign travelb by any HH member
Foreign visitorsb

Carriers

Noncarriers

11.1

8.5

.7

5.6

4.3

.8

.22

22.2

12.8

.25

2.2

.51

5.6

2.2

.35

8.7

1.6

.02

11.1

1.6

.004

8.7

4.5

.35

11.1

4.5

.2

17.4

6.1

.03

22.2

6.1

.007

0

8.0

.16

0

7.9

.22

Pa
.99
1.0

Pa

Abbreviations: 3GCR, third-generation cephalosporin resistant; Eb, Enterobacteriaceae; ESBL-P, extended-spectrum β-lactamase producing (confirmed by double-disk diffusion testing); HH, household; ICU, intensive care unit.
a
According to “N-1” χ2 test.
b
Within the previous year.
c
All subjects/children who travelled internationally had done so with a HH member (for AR Eb carriers and noncarriers).

coli, and 1 was Klebsiella pneumoniae. Antibiotic-susceptibility
testing results are presented in Table 4. Seventy-nine percent
of the isolates were resistant to trimethoprim-sulfamethoxazole, and 58% were resistant to ciprofloxacin. One (4%) isolate
was meropenem intermediate. The proportion of 3GCR isolates that were multidrug resistant was 58% overall, but it varied substantially among the study sites (KC, 33%; OAK, 100%;
Table 4.

NASH, 56%). All (6) 3GCR Enterobacteriaceae isolates from
OAK were ESBL-P and were multidrug resistant.
DISCUSSION

In this analysis of 519 healthy children in Oakland, Nashville, and
Kansas City, 4.4% were carriers of intestinal Enterobacteriaceae

3GCR Enterobacteriaceae Antibiotic Susceptibilities
Identification

Cipro

TMP-SMX

Gent

Cefepime

Pip-Tazo

Mero

ESBL

MDR

OAK1

3GCR Isolate

E coli

R

R

R

S

S

S

Y

Y

OAK2

E coli

R

R

R

I

I

S

Y

Y

OAK3

E coli

R

R

R

S

S

S

Y

Y

OAK4

E coli

R

R

S

S

S

S

Y

Y

OAK5

E coli

R

R

S

S

S

S

Y

Y

OAK6

E coli

R

R

S

S

S

S

Y

Y

KC1

E coli

S

S

S

S

R

S

N

N

KC2

E coli

S

R

S

S

S

S

N

N

KC3

E coli

S

S

S

S

S

S

Y

N

KC4

E coli

R

R

S

S

S

S

N

Y

KC5

E coli

S

R

S

S

S

S

Y

N

KC6

E coli

S

R

R

I

I

S

Y

Y

KC7

E coli

R

R

S

I

S

S

Y

Y

KC8

E coli

S

R

S

S

S

S

Y

N

KC9

E coli

R

S

S

S

S

S

Y

N

NASH1

E coli

R

S

R

I

S

S

Y

Y

NASH2

E coli

S

S

S

S

I

S

N

N

NASH3aa

E coli

R

R

R

S

I

S

Y

Y

NASH3ba

E coli

R

R

R

I

S

I

Y

Y

NASH4

E coli

R

R

S

S

S

S

Y

Y

NASH5

E coli

S

R

S

I

S

S

Y

N

NASH6

E coli

S

R

S

I

S

S

Y

N

NASH7

E coli

R

R

R

I

I

S

Y

Y

NASH8

K pneumoniae

S

R

S

R

S

S

N

N

58

79

33

38

25

4

79

58

Nonsusceptible, ESBL-P, or MDR
rate (%)

Abbreviations: 3GCR, third-generation cephalosporin resistant; Cipro, ciprofloxacin; ESBL-P, extended-spectrum β-lactamase producing (confirmed by double-disk diffusion testing); Gent, gentamicin; I, intermediate; KC, Kansas
City; MDR, multidrug resistant (defined as nonsusceptible to ≥1 agent in ≥3 antimicrobial classes); Mero, meropenem; N, no; NASH, Nashville; OAK, Oakland; Pip-Tazo, piperacillin-tazobactam; R, resistant; S, susceptible; TMPSMX, trimethoprim-sulfamethoxazole; Y, yes.
a
From the same subject.
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In our study, 3GCR and ESBL-P Enterobacteriaceae carriers
and noncarriers had antibiotic exposure within the previous
3 months in nearly equal proportions. Although recent antibiotic use has been associated with increased risk of ESBL-P
Enterobacteriaceae colonization in adults [28] and of ESBL
infections in children [7–9, 32], previous pediatric studies did
not show a consistent association of antibiotic intake with fecal
ESBL-P Enterobacteriaceae carriage [16, 20, 24, 26, 33]. In addition, a history of hospitalization in our subjects or in their HH
members was not a definitive risk factor for 3GCR or ESBL-P
Enterobacteriaceae colonization, which also is consistent with
data from adults [29]. The factors underlying new and sustained
fecal carriage of AR bacteria are complex and not fully characterized, but they seem to involve gastrointestinal disruption and
selective antibiotic pressure along with exogenous exposure to
AR Enterobacteriaceae [6, 13, 34].
It should be noted that the majority (57% [13 of 23]) of 3GCR
Enterobacteriaceae–colonized children lacked all the considered
risk factors of HH international travel, recent personal antibiotic exposure, and HH hospitalization history. These findings
support the idea that AR Enterobacteriaceae are truly present at
the community level and that potential sources, including the
food supply and general environment, might be widespread and
common [14, 29, 33, 35].
Children have a unique place in the transmission dynamics
(both acquisition and transfer) of AR bacteria. Infants in particular might have intimate contact with several adult caregivers and, by nature, are incontinent, have limited hygiene, and
frequently touch materials in their environment. The immature neonatal/infant intestine seems particularly vulnerable to
AR Enterobacteriaceae acquisition; the results of recent studies
highlighted the fact that the infant microbiome is unstable and
frequently populated with AR genes [36, 37]. Young children
also appear prone to protracted carriage: studies employing
molecular techniques of ESBL Enterobacteriaceae carrying
infants discharged from neonatal intensive care units (NICU)
[38, 39] and in international adoptees [40] have demonstrated
duration of colonization of up to 2 years. AR Enterobacteriaceae
strains can be regularly spread and then sustained within HH
and daycare settings; in 1 longitudinal investigation, the intrafamilial transmission rate from colonized post–neonatal intensive
care unit infants was 32% [39].
In addition, young children might have higher risk related
to AR Enterobacteriaceae carriage itself; ~5% of children have
at least 1 community-onset urinary tract infection by the age of
5 years (the pathogens of which, in healthy individuals, are presumed to be from their own intestinal flora). This risk is reflected
in US clinical laboratory-based surveillance data; approximately
half of 3GCR and ESBL-P pediatric isolates are from 1- to 5-yearolds, and the majority are from urine specimens [3].
Our study has important limitations. As a subinvestigation
of a larger study, questions added to assess exposures associated
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resistant to third-generation cephalosporins; 3.5% specifically
harbored ESBLs. This study is the largest community-based
characterization of AR Enterobacteriaceae colonization in
healthy children from North America to date. It is also 1 of very
few pediatric studies to have examined international travel as
a risk factor for either AR Enterobacteriaceae colonization or
infection [21].
Previous reports on AR Enterobacteriaceae colonization in
healthy children examined mainly ESBL-P (rather than 3GCR)
Enterobacteriaceae and were primarily from discrete sites in
Europe, with few from other regions. Although pediatric rates
from earlier studies in other northern European countries were
consistently <7% [15, 22–24], a recent analysis of 125 well 8- to
16-month-old children in northern Spain found a surprising 24%
overall prevalence of ESBL-P Enterobacteriaceae colonization
[17]. Data from children in Africa and Asia, which might inform
community-level colonization, are limited but have consistently
indicated high prevalences; children screened on presentation
to medical facilities in Niger and Guinea-Bissau had ESBL-P
Enterobacteriaceae rates of 32.6% and 31%, respectively [17, 25],
and in nearly 400 healthy <6-year-olds attending childcare centers in Laos (2011), the ESBL-P Enterobacteriaceae carriage rate
was 23% [26]. Existing data from adults in North America itself
are minimal, and ESBL community carriage (based on travelers before departure [12], healthy military personnel [27], and
vegetarians living in the Midwest [28]) might be best estimated
to be ~2% [29]. In this context, ESBL-P Enterobacteriaceae rates
found in this study (3.5% overall and 5.7% in children aged 1 to
<2 years) are higher than ever reported in healthy Americans
and are generally comparable to those in European countries.
In various case-control analyses [30, 31] and in studies that
examined fecal carriage of travelers before and after trips abroad
[10, 13], international travel was found to be a risk factor for
ESBL-P Enterobacteriaceae colonization and infection in adults.
Investigations of stool from Scandinavian travelers found that
>20% acquire ESBL-P Enterobacteriaceae after time abroad
(trips typically ~2 weeks); the rates were highest for those who
visited destinations in Asia and were up to 80% for those who
had diarrhea and took antibiotics during their journey [10,
13]. A recent comprehensive meta-analysis found that international travel conferred a higher risk for ESBL colonization than
any other factor (relative risk, >4) [29]. A separate systematic
review in which available community carriage and population
census data were used estimated there are >1.1 billion ESBL-P
Enterobacteriaceae carriers in southeast Asia [14]; these and
other authors have described what has become a globalization
of the CTX-M ESBL enzyme (in particular), with international
travel and migration being key drivers [14, 31]. The findings of
our analysis reflect the existing literature in adults; children with
a personal history of foreign travel were 5 times more likely to
be 3GCR Enterobacteriaceae carriers that those without such as
history (20% [2 of 10] vs 4.1% [21 of 509], respectively; P = .015)
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